BRIDGEWATER, N.J. (September 9th, 2014) – Senesco Technologies, Inc. (OTCQB: SNTI) (the “Company” or “Sevion”), a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc. The Company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the Company’s goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.
“Sevion brings together several cutting-edge platform technologies. Novel antibody discovery systems and scaffolds address important therapeutic targets previously inaccessible with biologics, including GPCRs and ion channels, and nucleic acid-loaded nanoparticles leverage our deep understanding of the eIF5A ‘apoptosis gene’,” said Ronald Martell, chief executive officer. “This new corporate identity will allow us to build broader awareness of our innovative platforms and objectives to advance a high-value pipeline of proprietary and partnered product candidates.”
Mr. Martell concluded: “As we launch this new identity, our strategy will focus on several components, including our clinical asset SNS01-T, moving two promising antibodies toward Investigational New Drug (IND) status and leveraging our pipeline and platforms through partnerships, while looking to in-licensing opportunities that are consistent with our therapeutic areas and scientific focus.”
The company’s website is now available at SevionTherapeutics.com.
About Sevion Therapeutics
Sevion Therapeutics is a clinical-stage company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds, eIF5A apoptotic regulatory systems, and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to integrate the Fabrus science and operations, including the rebranding of the Company as Sevion Therapeutics; the Company’s ability to continue as a going concern; the Company’s ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company’s gene and antibody technology; the approval of the Company’s patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
David Pitts, Argot Partners